Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603304 · ClinicalTrials.gov registry record · Phase 3
Complementary and Alternative Medicine for Urological Symptoms(CAMUS)
A Phase 3 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 3
- Development phase
- 369
- Enrollment target
NCT00603304 is a Phase 3 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 369 participants.
The verdict
NCT00603304, a Phase 3 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 369 participants
- Enrollment target
Study Summary
The CAMUS trial will test Saw palmetto in about 369 men. Men who decide to be part of the CAMUS trial will be given one out of two possible treatments at random. One out of every two men would get an inactive placebo treatment. One out of every two men would get Saw palmetto pills. This kind of scientific study is the best way to find out if the plant extracts really work to prevent men with benign prostatic hyperplasia (BPH) from getting worse. During the study, men will not know which of the two treatments they are assigned to. They will be followed very closely by a study team every 12 weeks to see how they are doing. Men in the CAMUS trial will be studied over 72 weeks. Tests and all medications needed as part of the study will be provided at no charge to the participant. Participants will be responsible for all other costs not associated with the study tests and medications. All information on study participants will be held in the strictest confidence and no one would have access to patient information other than the required authorized health care and research personnel.
Interventions
- DRUG Saw Palmetto - first 24 weeks
- DRUG Placebo - first 24 weeks
- DRUG Saw Palmetto - weeks 24 - 48
- DRUG Placebo - weeks 24 - 48
- DRUG Saw Palmetto - weeks 48 - 72
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00603304
The ClinicalTrials.gov registry entry for NCT00603304 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 369 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Saw Palmetto - first 24 weeks is the first listed.
NCT00603304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00603304 about?
NCT00603304 is a clinical study titled "Complementary and Alternative Medicine for Urological Symptoms(CAMUS)". The CAMUS trial will test Saw palmetto in about 369 men. Men who decide to be part of the CAMUS trial will be given one out of two possible treatments at random. One out of every two men would get an inactive placebo treatment. One out of every two men would get Saw palmetto pills. This kind of sci...
What is the current status of trial NCT00603304?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 369 participants. The study started on 2008-02. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00603304?
The interventions under investigation include: Saw Palmetto - first 24 weeks (DRUG), Placebo - first 24 weeks (DRUG), Saw Palmetto - weeks 24 - 48 (DRUG), Placebo - weeks 24 - 48 (DRUG), Saw Palmetto - weeks 48 - 72 (DRUG).
Who is sponsoring clinical trial NCT00603304?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.